Differential expression of immune activation markers in T cells from patients with multiple myeloma
-
By
-
Jiaoya Lin
-
Xin Zhang
-
Yifei Zhao
-
Lan Luo
-
Hong Yuan
-
Ling Zhong
-
May 20, 2026
-
Clinical Scorecard: Variations in Immune Activation Markers in T Cells from Individuals with Multiple Myeloma
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Alterations in the tumor immune microenvironment (TIME) and T cell activation status contribute to therapy resistance in MM. |
| Target Population | |
| Care Setting | |
Key Highlights
- Increased proportions of CD4+ and CD8+ central memory T cells in MM patients, with specific percentages.
- Decreased CD4+ effector memory T cells and CD4+ TEMRA cells in MM patients, with specific percentages.
- Elevated activation markers in specific T cell subsets in MM compared to healthy controls, with data.
- Dysregulated immune responses facilitate immune escape in MM, requiring further elaboration.
- Understanding T cell activation is crucial for optimizing immunotherapeutic strategies, with examples.
Guideline-Based Recommendations
Diagnosis
Management
- Consider T cell-engaging therapies (TCEs) based on T cell functional status, including specific examples.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Therapeutic efficacy may be limited in cases of severe immune exhaustion, impacting treatment decisions.
Clinical Best Practices
- Monitor T cell activation status to guide immunotherapy decisions, using specific profiling techniques.
- Evaluate the tumor microenvironment for potential therapeutic targets, with examples.
- Incorporate immune profiling in treatment planning for MM patients, detailing methods.
Related Resources & Content
